Our EQA scheme timetable was impacted by the COVID-19 pandemic. Please click the link below for the revised timetable (published 01.07.2020).
Please visit the READ MORE link below to learn more about this initiative.
Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.
Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
Membership of EMQN gives your laboratory access to world class resources in genomics to help improve your performance.
The latest news and press releases
EMQN Best Practice Guidelines for Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase Deficiency - https://t.co/JI4YXmsqWb
EMQN is recruiting new assessors for our Molecular Pathology schemes and new pilot schemes. Interested in volunteer… https://t.co/g0V9cM0hpK
Provisional results from 2020 Germline EQA schemes have been published today - click https://t.co/6YcxDi53Cz for more details.
EMQN Best Practice Guidelines for DMD Published - https://t.co/09D0e3vFRr